2023
Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848
Tchelebi L, Winter K, Abrams R, Safran H, Regine W, McNulty S, Wu A, Du K, Seaward S, Bian S, Aljumaily R, Shivnani A, Knoble J, Crocenzi T, DiPetrillo T, Roof K, Crane C, Goodman K. Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848. International Journal Of Radiation Oncology • Biology • Physics 2023, 118: 107-114. PMID: 37598723, PMCID: PMC10843017, DOI: 10.1016/j.ijrobp.2023.08.014.Peer-Reviewed Original ResearchConceptsTarget volumeRadiation therapy quality assuranceRadiation therapyPlanning target volumeClinical treatment volumeGross target volumePretreatment QAContouring atlasTreatment planningResectable pancreatic head adenocarcinomaRT planningIntensity modulated RTQA analysisPancreatic head adenocarcinomaNRG Oncology RTOGPracticing radiation oncologistsReal-time quality assuranceTreatment volumeEffects of RTConcurrent fluoropyrimidineConformal RTAdjuvant chemotherapyRadiation oncologistsQuality assurancePancreas cancer
2014
Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials
Min C, Bangalore S, Jhawar S, Guo Y, Nicholson J, Formenti SC, Leichman LP, Du KL. Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials. Oncology 2014, 86: 79-85. PMID: 24435019, DOI: 10.1159/000354641.Peer-Reviewed Original ResearchConceptsDisease-free survivalAdjuvant chemoradiationSurgical resectionOverall survivalRandomized trialsGastric cancerMantel-Haenszel random-effects modelHigher disease-free survivalCategory 1 recommendationNew systemic agentsR0 surgical resectionCurrent national guidelinesSignificant differencesRandom-effects modelAdjuvant chemotherapyPerioperative chemotherapyChemotherapy regimenChemoradiation therapySystemic agentsPrimary outcomeGastric adenocarcinomaClinical trialsChemoradiationNational guidelinesResection